---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011149"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:45:47.076450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q2 net loss $0.53/sh; cash $16.5M; clinical activity in APR-1051 and ATRN-119

## Summary
- Cash and cash equivalents $16.5M as of June 30, 2025, down from $22.8M at Dec 31, 2024; runway into Q2 2026.
- Q2 2025 operating loss $3.4M vs $3.8M in Q2 2024; net loss $3.2M ($0.53 per share) vs $3.5M ($0.58 per share).
- Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051: 3 patients with stable disease at 70mg/100mg; dose escalation to 150mg planned.
- Phase 1/2a ABOYA-119 trial of ATRN-119: 7 patients stable disease, 3 with tumor shrinkage (7%-21%) at 550mg BID; now dosing 400mg BID.
- Additional safety/efficacy data expected H2 2025; RP2D for ATRN-119 and dose-escalation completion for APR-1051 expected H1 2026.

## SEC filing metadata
- accession: 0001558370-25-011149
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025011149/0001558370-25-011149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025011149/apre-20250812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011149
- JSON: https://secwatch.observer/filing/0001558370-25-011149.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.